SENS
Neutral signalScored 2026-08-22 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Senseonics Holdings, Inc.
- Nom
- Senseonics Holdings, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $399.5M
- Employés
- 130
- PDG
- Timothy T. Goodnow
- Site web
- https://www.senseonics.com
- Marché
- BBNXDXCMGCTKMMEDPFSAPODD
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 13 953,284 titres (~125 300,49 $ US)
- Insiders
- ROEDER DOUGLAS A
- Total bought
-
$125,300
Avg buy (VWAP, 90d window) $8.98 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-19
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-19 | ROEDER DOUGLAS A | Buy · P | 13,953 | $8.98 | $125,300 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-22 Drivers: fundamentals. Moteurs : fondamentaux.
Despite a compelling insider cluster buy of ~14M shares post-earnings with raised 2026 guidance (~120% revenue growth), SENS's severely distressed fundamentals — persistent negative operating margins, extreme cash burn…
The first sentence of the analysis written for SENS on 2026-08-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.83 · operating margin -194% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 44.7% | 2.4% | 13.8% | 16.6% | -5.9% | |
| Ebit Margin | -182.0% | -312.3% | -220.1% | -418.7% | -2089.6% | |
| Ebitda Margin | -177.7% | -305.7% | -214.4% | 987.3% | -2080.5% | |
| Operating Profit Margin | -193.8% | -333.0% | -337.7% | -418.7% | -418.1% | |
| Pretax Profit Margin | -196.0% | -349.8% | -269.7% | 867.2% | -2211.9% | |
| Continuous Operations Profit Margin | -196.0% | -349.8% | -269.7% | 867.2% | -2211.9% | |
| Net Profit Margin | -196.0% | -349.8% | -269.7% | 867.2% | -2211.9% | |
| Bottom Line Profit Margin | -196.0% | -349.8% | -269.7% | -409.7% | -2211.9% | |
| Current Ratio | 4.827 | 2.354 | 7.535 | 5.122 | 7.851 | |
| Quick Ratio | 4.552 | 2.240 | 7.026 | 4.890 | 7.508 | |
| Solvency Ratio | -1.036 | -0.659 | -0.577 | 0.794 | -0.784 | |
| Cash Ratio | 1.665 | 1.920 | 4.387 | 1.137 | 1.819 | |
| Price To Earnings Ratio | -3.325 | -4.188 | -5.182 | 3.394 | -3.708 | |
| Price To Earnings Growth Ratio | 0.099 | -0.307 | 0.038 | -0.024 | 0.571 | |
| Forward Price To Earnings Growth Ratio | 0.099 | -0.307 | 0.038 | -0.024 | 0.571 | |
| Price To Earnings Diluted Ratio | -3.325 | -4.188 | -5.182 | -9.493 | -3.708 | |
| Price To Earnings Diluted Growth Ratio | 0.099 | -0.307 | -3.748 | 0.112 | 0.571 | |
| Price To Book Ratio | 3.773 | -19.913 | 9.044 | -187.108 | -6.078 | |
| Price To Sales Ratio | 6.533 | 14.670 | 14.459 | 29.409 | 82.457 | |
| Price To Free Cash Flow Ratio | -3.823 | -5.257 | -4.591 | -7.234 | -20.033 | |
| Price To Operating Cash Flow Ratio | -3.896 | -5.452 | -4.614 | -7.269 | -20.108 | |
| Debt To Assets Ratio | 0.328 | 0.608 | 0.346 | 0.424 | 0.323 | |
| Debt To Equity Ratio | 0.678 | -3.688 | 1.335 | -29.261 | -0.346 | |
| Debt To Capital Ratio | 0.404 | 1.372 | 0.572 | 1.035 | -0.529 | |
| Long Term Debt To Capital Ratio | 0.368 | 1.912 | 0.535 | 1.048 | -0.476 | |
| Financial Leverage Ratio | 2.068 | -6.067 | 3.861 | -68.972 | -1.072 | |
| Working Capital Turnover Ratio | 0.484 | 0.272 | 0.185 | 0.128 | 0.196 | |
| Operating Cash Flow Ratio | -2.428 | -1.556 | -4.066 | -2.107 | -3.049 | |
| Operating Cash Flow Sales Ratio | -1.677 | -2.691 | -3.134 | -4.046 | -4.101 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.037 | 1.005 | 1.005 | 1.004 | |
| Debt Service Coverage Ratio | -11.502 | -2.404 | -4.321 | 4.720 | -14.482 | |
| Interest Coverage Ratio | -13.803 | -8.871 | -6.805 | -3.669 | -3.420 | |
| Short Term Operating Cash Flow Coverage Ratio | -119.212 | -3.003 | 0.000 | -4.256 | -19.165 | |
| Operating Cash Flow Coverage Ratio | -1.429 | -0.990 | -1.469 | -0.880 | -0.873 | |
| Capital Expenditure Coverage Ratio | -52.983 | -27.005 | -200.466 | -212.538 | -267.038 | |
| Dividend Paid And Capex Coverage Ratio | -52.983 | -27.005 | -200.466 | -212.538 | -267.038 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.690 | -4.601 | -6.162 | 3.223 | -4.071 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 44.7% | ▲42.3% | ▲30.4% |
| Ebit Margin | -182.0% | ▲130.3% | ▲462.6% |
| Ebitda Margin | -177.7% | ▲128.0% | ▲180.5% |
| Operating Profit Margin | -193.8% | ▲139.2% | ▲146.5% |
| Pretax Profit Margin | -196.0% | ▲153.8% | ▲236.0% |
| Continuous Operations Profit Margin | -196.0% | ▲153.8% | ▲236.0% |
| Net Profit Margin | -196.0% | ▲153.8% | ▲236.0% |
| Bottom Line Profit Margin | -196.0% | ▲153.8% | ▲491.4% |
| Current Ratio | 4.827 | ▲2.474 | ▼-0.711 |
| Quick Ratio | 4.552 | ▲2.312 | ▼-0.691 |
| Solvency Ratio | -1.036 | ▼-0.377 | ▼-0.584 |
| Cash Ratio | 1.665 | ▼-0.255 | ▼-0.520 |
| Price To Earnings Ratio | -3.325 | ▲0.863 | ▼-0.723 |
| Price To Earnings Growth Ratio | 0.099 | ▲0.406 | ▲0.024 |
| Forward Price To Earnings Growth Ratio | 0.099 | ▲0.406 | ▲0.024 |
| Price To Earnings Diluted Ratio | -3.325 | ▲0.863 | ▲1.854 |
| Price To Earnings Diluted Growth Ratio | 0.099 | ▲0.406 | ▲0.754 |
| Price To Book Ratio | 3.773 | ▲23.686 | ▲43.830 |
| Price To Sales Ratio | 6.533 | ▼-8.137 | ▼-22.973 |
| Price To Free Cash Flow Ratio | -3.823 | ▲1.434 | ▲4.364 |
| Price To Operating Cash Flow Ratio | -3.896 | ▲1.556 | ▲4.372 |
| Debt To Assets Ratio | 0.328 | ▼-0.280 | ▼-0.078 |
| Debt To Equity Ratio | 0.678 | ▲4.366 | ▲6.934 |
| Debt To Capital Ratio | 0.404 | ▼-0.968 | ▼-0.167 |
| Long Term Debt To Capital Ratio | 0.368 | ▼-1.544 | ▼-0.309 |
| Financial Leverage Ratio | 2.068 | ▲8.135 | ▲16.105 |
| Working Capital Turnover Ratio | 0.484 | ▲0.212 | ▲0.231 |
| Operating Cash Flow Ratio | -2.429 | ▼-0.872 | ▲0.213 |
| Operating Cash Flow Sales Ratio | -1.677 | ▲1.014 | ▲1.453 |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | ▼-0.018 | ▲0.005 |
| Debt Service Coverage Ratio | -11.502 | ▼-9.097 | ▼-5.904 |
| Interest Coverage Ratio | -13.803 | ▼-4.932 | ▼-6.489 |
| Short Term Operating Cash Flow Coverage Ratio | -119.212 | ▼-116.209 | ▼-90.085 |
| Operating Cash Flow Coverage Ratio | -1.429 | ▼-0.439 | ▼-0.301 |
| Capital Expenditure Coverage Ratio | -52.983 | ▼-25.978 | ▲99.023 |
| Dividend Paid And Capex Coverage Ratio | -52.983 | ▼-25.978 | ▲99.023 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.690 | ▲0.911 | ▼-0.629 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $230.3M | $329.7M | $323.7M | $482.0M | $1.13B | |
| Enterprise value | $231.2M | $316.1M | $295.8M | $521.6M | $1.16B | |
| EV / Sales | 6.56x | 14.07x | 13.21x | 31.82x | 84.70x | |
| EV / Op. cash flow | -3.91x | -5.23x | -4.22x | -7.87x | -20.66x | |
| EV / Free cash flow | -3.84x | -5.04x | -4.20x | -7.83x | -20.58x | |
| EV / EBITDA | -3.69x | -4.60x | -6.16x | 3.22x | -4.07x | |
| Net debt / EBITDA | -0.01x | 0.20x | 0.58x | 0.24x | -0.11x | |
| Current ratio | 4.83x | 2.35x | 7.54x | 5.12x | 7.85x | |
| Income quality | 0.86x | 0.77x | 1.16x | -0.47x | 0.18x | |
| Graham net-net | $1 | -$1 | $1 | -$1 | -$12 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 107.7% | 112.0% | 122.5% | -207.1% | 105.9% | |
| Working capital | $93.2M | $52.6M | $112.8M | $129.7M | $126.0M | |
| Invested capital | $98.2M | $56.7M | $114.0M | $130.8M | $127.3M | |
| Return on assets | -54.7% | -78.3% | -43.7% | 80.0% | -152.1% | |
| Operating ROA | -60.3% | -62.7% | -47.9% | -36.4% | -48.7% | |
| Return on tangible assets | -55.1% | -78.7% | -43.7% | 80.0% | -152.1% | |
| Return on equity | -113.2% | 474.9% | -168.7% | -5517.0% | 163.0% | |
| Return on invested capital | -66.7% | -91.1% | -62.3% | -42.2% | -31.0% | |
| Return on capital employed | -67.0% | -121.5% | -62.5% | -46.9% | -31.7% | |
| Earnings yield | -30.0% | -23.8% | -18.7% | 29.5% | -26.8% | |
| Free cash flow yield | -26.2% | -19.0% | -21.8% | -13.8% | -5.0% | |
| Capex / Op. cash flow | -1.9% | -3.7% | -0.5% | -0.5% | -0.4% | |
| Capex / Depreciation | 1226.4% | 151.8% | 27.4% | 31.7% | 16.9% | |
| Capex / Sales | 3.2% | 10.0% | 1.6% | 1.9% | 1.5% | |
| SG&A / Sales | 148.9% | 152.3% | 133.7% | 193.0% | 213.2% | |
| R&D / Sales | 89.6% | 183.1% | 217.7% | 242.4% | 199.0% | |
| Stock comp / Sales | 28.8% | 41.1% | 38.7% | 52.6% | 66.0% | |
| Intangibles / Total assets | 0.6% | 0.5% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 129d | 131d | 108d | 62d | 64d | |
| Days payables outstanding | 76d | 53d | 86d | 11d | 30d | |
| Operating cycle | 254d | 205d | 274d | 257d | 224d | |
| Cash conversion cycle | 178d | 151d | 187d | 246d | 193d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-07 Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
- 2026-08-07 Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
- 2026-08-06 Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.
- 2026-07-21 Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.
- 2026-06-29 Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength? Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-06-11 Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.
- 2026-06-06 Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM''s differentiated approach and high performance
- 2026-06-06 Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
- 2026-06-01 Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026 GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana.